Alex Zhavoronkov: Obesity, Longevity, AI-Designed Drugs, Billion Dollar Pharma Deals & the End of “Dinosaur AI"
Failed to add items
Add to basket failed.
Add to wishlist failed.
Remove from wishlist failed.
Adding to library failed
Follow podcast failed
Unfollow podcast failed
Alex Zhavoronkov: Obesity, Longevity, AI-Designed Drugs, Billion Dollar Pharma Deals & the End of “Dinosaur AI"
-
Narrated by:
-
By:
What happens when artificial intelligence starts designing medicines faster than the pharmaceutical industry can comprehend?
In this explosive conversation, Dr. Will Soliman sits down with Alex Zhavoronkov, CEO, one of the most provocative voices in AI drug discovery and the founder of Insilico Medicine, to discuss the future of medicine, longevity, biotech, and the AI arms race transforming pharma.
Fresh off Insilico’s multibillion-dollar deal with Eli Lilly, Alex explains why traditional pharmaceutical models are being disrupted, how AI-designed drugs are moving from theory to reality, and why most companies are still operating with what he calls “dinosaur AI.”
Hear why Alex says China is beating everyone in drug discovery and new patents, and its impact.